As Ackman Liquidates, ValueAct Gets More Invested In Valeant

From Hedge Funds
March 16, 2017 - 5:43pm
Just days after Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares took a steep tumble below the $11 level, the stock is almost back to an important level at $12. The stock saw an after-hours move higher Thursday following a notable Form 4 filing and the ensuing 13D filing. The filing showed the purchase of 3 million shares by ValueAct ...Full story available on Benzinga.com


Continue reading this article »